Finanzas de CRISPR Therapeutics AG (CRSP)CRSPCRISPR Therapeutics AG

Evaluating the bottom line, CRISPR Therapeutics AG maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1127.55%, while the net margin is -895.33%. These profitability ratios, combined with a Return on Equity (ROE) of -26.09%, provide a clear picture of how effectively CRSP converts its operational activities into shareholder value.

In the context of the broader market, CRSP competes directly with industry leaders such as SRRK and COGT. With a market capitalization of $5.16B, it holds a significant position in the sector. When comparing efficiency, CRSP's gross margin of 100.00% stands against SRRK's N/A and COGT's N/A. Such benchmarking helps identify whether CRISPR Therapeutics AG is trading at a premium or discount relative to its financial performance.

CRISPR Therapeutics has shown declining revenue with only $10,181,000 in Q2 2026, and a net income loss of -91,154,000 USD. The gross margin remains high at 100%, but the overall financial health is concerning with a negative net margin of -895.33%.